Baxter International (NYSE:BAX) Posts Earnings Results, Beats Expectations By $0.06 EPS

Baxter International (NYSE:BAX) posted its earnings results on Thursday. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.06, FiscalAI reports. The firm had revenue of $2.98 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%. The business’s revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.69 earnings per share.

Here are the key takeaways from Baxter International’s conference call:

• Third-quarter results exceeded expectations: Sales rose 5% organically to approximately $3 billion, with broad-based growth led by Advanced Surgery, drug compounding, and infusion systems. Baxter raised its 2026 organic sales growth outlook to 3%-4% and lifted the low end of adjusted EPS guidance to $2.05-$2.15.
• Cash flow and deleveraging improved: Third-quarter free cash flow was $448 million, bringing year-to-date free cash flow to $705 million. Baxter also completed a $600 million tender offer that retired $854 million of debt and remains confident in reaching approximately 3x net leverage by year-end.
• Operational improvements continued across the portfolio, including better on-time shipments, improved quality metrics, cost savings, and more than 700 Baxter GPS continuous-improvement initiatives completed year to date. Advanced Surgery grew 12%, while HST margins expanded 140 basis points.
• Quality and portfolio actions create near-term pressure: Baxter will discontinue cephalosporin production at its Round Lake facility following supply and FDA warning-letter issues; the products are expected to contribute approximately $50 million in 2026 sales and $30 million in operating income. Management also flagged 2027 headwinds from product exits, the loss of tariff-refund benefits, inflation, tariffs, and the end of Vantive-related TSA services.

Baxter International Stock Down 4.1%

Shares of BAX traded down $0.96 during mid-day trading on Friday, reaching $22.54. The company had a trading volume of 6,160,271 shares, compared to its average volume of 7,811,814. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.32 and a current ratio of 1.95. The company has a market capitalization of $11.65 billion, a price-to-earnings ratio of -10.90, a price-to-earnings-growth ratio of 3.85 and a beta of 0.65. The firm has a 50-day moving average price of $24.65 and a 200 day moving average price of $21.35. Baxter International has a 52 week low of $15.73 and a 52 week high of $30.00.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, November 27th will be given a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, November 27th. Baxter International’s payout ratio is currently -1.93%.

Baxter International News Summary

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Baxter reported third-quarter adjusted earnings of $0.58 per share and revenue of $2.98 billion, exceeding analyst estimates of $0.52 and $2.91 billion, respectively. Revenue increased 5% year over year, supported by broad-based segment growth. Baxter International Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management raised its full-year 2026 earnings outlook, signaling confidence in demand and operating performance. The guidance increase is supportive for the stock, although ongoing margin pressure remains a concern. Baxter Raises 2026 Earnings Guidance
• Neutral Sentiment: Baxter declared a quarterly dividend of $0.01 per share, payable January 4 to shareholders of record November 27. The annualized yield is approximately 0.2%, so the payment provides limited income support for investors. Baxter Raises Guidance and Declares Dividend
• Negative Sentiment: The company received an FDA warning letter citing cGMP violations. The notice could increase compliance costs, require remediation, and create risks to manufacturing or product approvals, potentially offsetting the benefit of the earnings beat and higher guidance. Baxter Received FDA Warning Letter Over cGMP Violations

Analysts Set New Price Targets

Several brokerages have commented on BAX. Stifel Nicolaus upped their price objective on shares of Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a report on Tuesday, July 28th. Jefferies Financial Group reissued a “hold” rating and issued a $25.00 price target on shares of Baxter International in a research note on Thursday. Zacks Research raised Baxter International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Wells Fargo & Company upped their target price on Baxter International from $23.00 to $25.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, Barclays began coverage on Baxter International in a research note on Wednesday, October 7th. They issued an “underweight” rating and a $20.00 target price for the company. One research analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $22.45.

About Baxter International

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.